Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2022

View Archived Issues

Targeting RNF41 promotes liver regeneration in mice

PTPRK predicts poor prognosis in patients with pancreatic cancer

Mindset Pharma discovers 5-HT2A receptor agonists

University of Queensland, James Cook University describe new therapeutic peptides

New protein kinase B inhibitors identified at Nanjing Zhengda Tianqing Pharmaceutical

Jiangsu Zhengda Qingjiang Pharmaceutical presents SLC22A12 inhibitors

New Gly12Cys mutant GTPase KRAS inhibitors patented by Abbisko Therapeutics

ACT-02 improves neurodegeneration in mouse model of PD

Knockout models may reveal role of CRIPTO in castration-resistant prostate cancer

SERPINA1 is associated with poor prognosis and liver metastasis in gastric cancer

DTX-P7, a novel peptide-conjugated drug with efficacy in NSCLC

FGFR inhibition suppresses RFA-driven HCC tumorigenesis

Janssen, Johnson & Johnson present new compounds for the treatment of hepatitis B

MYC modulator OTX-2002 shows promising results in HCC treatment

New TYK2 inhibitors synthesized at Shenzhen Chipscreen Biosciences

RNA-binding protein helps colon cancer cells persist

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...